AbGn-268 is under clinical development by AltruBio and currently in Phase I for Ulcerative Colitis. According to GlobalData, Phase I drugs for Ulcerative Colitis have an 84% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AbGn-268’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AbGn-268 overview

AbGn-168H2 (leiolizumab) is under development for the treatment of inflammation and other autoimmune disorders, ulcerative colitis and solid organ transplantation. The drug candidate is a humanized monoclonal antibody. It acts as PSGL-1 agonist. The drug candidate is designed by using linker-payload platform technology. It was also under development of psoriatic arthritis. It is administered through subcutaneous route of administration.

AltruBio overview

AltruBio formerly, AbGenomics International is a clinical-stage biopharmaceutical company. It develops therapeutics for inflammatory or autoimmune diseases and cancers. The company’s products portfolio include pipeline products, therapeutic products, neihulizumab, bio-therapeutics, preclinical and oncology products. It pipeline products include neihulizumab AbGn-168H, leiolizumab AbGn-268, AbGn-107 and AbGn-207. AltruBios’ thearupitic areas comprise gastric and pancreatic cancer, GI tumors, immune-mediated inflammatory diseases, antigen positive cancer and colorectal cancers, among others. The company operates its offices in the US and Taiwan. AltruBio is headquartered in Redwood, California, the US.

For a complete picture of AbGn-268’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.